Mortality after percutaneous coronary intervention in cardiogenic shock: a predictive model based on 1,869 consecutive patients in the ACC-NCDR registry  by Klein, Lloyd W. et al.
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624FO-6 Emergent Angioplaaty for Acute Myocardial Infarction 
at a Community Hospital Without On-Site Cardiac 
Surgery 
Mandeeo Sinoh, Kirk N. Garratt, Ryan J. Lennon, Michael A. Kjelsberg, Bernard J. 
Gersh, Peter B. Berger, Fards K. Timimi, Robert J. Houlihan, Kevin T. Cragun, 
Christopher H. Crocker, David R. Holmes, Jr., Henry H. "ling, Mayo Clinic, Rochester, 
Minnesota. 
Background: Percutaneous coronary intervention (PCI) for acute myocardial infarction 
(AMI) at hospitals without on-site cardiac surgery (CABG) remains controversial. We 
studied the safety and efficacy of PCI perfoi'med for AMI at Immanuel St. Joseph's Hospi- 
tal (IS,J), with no on-site CABG, with our affiliate, St. Mary's Hospital (SMH}, the nearest 
center (85 miles away) with on-site CABG. 
Method and Results: ISJ and SMH are linked by a T3 telemedicine line to enable on line 
consultation with cardiology and surgical staff at SMH. We compared the results of emer- 
gent PCI for AMI (defined as ST-segment elevation/new LBBB, or non-ST -segment ele- 
vation MI with ongoing chest pain) from 3/00 to 8/01 at ISJ (n=94) with matched controls 
at SMH. Multiple logistic regression analysis developed a propensity score based on clin- 
ical and angiographic variables. The two groups were balanced for age, ST-segment ele- 
vation, anterior infamt, gender, prior revaeculadzation, congestive heart failure, 
hypertension, smoking status, and renal or peripheral vascular disease. The in-hospital 
outcomes were similar in the two groups (see Table). No patient required urgent CABG 
due to procedural related complication. 
Conclusion: Our initial experience of emergent PCI for AMI utilizing telemedicine at a 
community hospital without on-site CABG is favorable, and the results are comparable to 
those at a tertiary facility with on-site CABG. These data support the new ACC/AHA 
Guidelines for PCI for AMI at a center without on-site CABG. 
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Variable ISJ Hospital Saint Mary's Hospital P-Value 
N=g4 (%) N=94(%) 
Age, yr 63.1+12.3 62.9+11.8 0.91 
Male 72(77) 67(71 ) 0.41 
ST-elevation MI 67(71 ) 67(71 ) 1.0 
Anterior M I 18(19) 18(19) 1.0 
Procedural success 88(94) 90(96) 0.52 
In-hospital death 3(3) 2(2) 0.65 
CABG<24 hours 0(0) 0(0) 
In-hospital death, QMI, CABG 4(4) 3(3) 0.70 
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1125-3 Late Evolution of Dilated Coronary Lesions 
Walter Desmet, Joseph Dens, Jan Piessens, UZ Gasthuisberg, Leuven, Belgium. 
Background: Smaller studies have suggested late regression of the dilated site after 
coronary angioplasty. The aim of this study was to evaluate with quantitative coronary 
angiography (QCA) the natural history of changes that occur in the dilated segment 
between 6 months and 3 years follow-up after angioplasty. 
Methods: We studied a subpopulation of the NICOLE (Nlsoldipine for COronary artery 
disease in LEuven)-study, in which patients underwent a control angiography 6 months 
and 36 months after coronary angioplasty. Of 826 patients who underwent successful 
angioplasty of one or more lesions, a total of 359 had a first control angiography after 
187±11 days (6M) and a second follow-up angiography after 1050~149 days (36M) with- 
out intervening revascularization of any target vessel. The 435 dilated lesions in these 
patients were subdivided in 4 categories depending on their degree of stenosis (%DS) at 
the time of the first control angiogram. 
Results: 
Subgroup Number of %DS %DS Change p-value 
%DS 6 M lesions at 5 M at 36 M 36M-6 M Change 
<25 69 19.0 _+ 5.6 32.0 + 12.9 13.1 + 13.8 < 0.0001 
25-60 290 38.0 + 6.5 38.8 + 10.2 0.8 + 10.5 0.2 
51-75 71 58.4±6.8 47.6±14.5 -10.9+14.9 <0.0001 
>75 5 82.2±6.6 54.0_+8.0 -28.2+7.1 0.0009 
Mean + SD are given 
Conclusion: Dilated coronary lesions with > 50 %DS 6 months after coronary angio- 
plasty show significant regression over the ensuing 2.5 years, while lesions of intermedi- 
ate severit~ (25-50 %DS) remain stable and minimal lesions still progress. 
These findings may aid in clinical decision making. 
1125-4 Prevention of Clinical Events and Restenosis After 
Percutaneous Tranalumlnal Coronary Angloplasty With 
Trapldil: Results of the STARC II Study 
Aleardo Maresta, Marco Balducelli, Spencer B. King Ill, Roberto Latini, Tiziano Moccetti, 
Alessandro Monici-Preti. Elisabetta Varani, Aldo P. Maggioni, for the STARC II 
Investigators, Ospedale S. Maria delle Croci, Ravenna, Italy, Istituto Mario Negri, Milano, 
Italy. 
Background. Still 30-40% of pts have a significant degree of restenosis after PTCA even in 
the stent era. Trapidil (T), a drug with antiplatelet and antiproliferative activity (platelet- 
derived growth factor antagonism) was shown to prevent post-PTCA restenosis in humans. 
STARC I study, showed a significant reduction in restenosis (24.2% T vs 39.7% ASA). 
Methods. To confirm these data, STARC II tdal tested a 6-month administration of T in 933 
pts undergoing elective PTCA (200 mg tld vs placebo (P) on top of ASA), on the 1-year 
combined end-point of death, reinfarction and need for repeat revasculadzatlon. The study 
was randomized, multicenter, double-blind. A subgroup of 305 pts was also randomized to 
repeat coronary angiography (CA) at 6 months with central reading. 
Results. Baseline clinical and angiographic characteristics were similar in the two study 
groups. Stent was implantated in 57% of the pts. Pdmary end-point occurred in 18.0% of P 
and in 20.4% of T groups(p--0.37). When recurrence or worsening of angina was added as 
further clinical end-point, this summed up to 23.0% in P vs 27.7% in T group (p=0.12). 
Treatment had to be discontinued for untowards effects in 5.0% and 9.6% of pts, respec- 
tively in P and T groups (p=0.O2). The angiographic substudy showed a slightly better final 
minimal uminal diameter (MLD) for T treated pts (1.7¢0.64 mm vs 1.59±0.67 mm) and less 
MLD late loss (0.48 vs 0.65 mm). This was parficulady evident in patients treated with bal- 
loon alone (0.21 vs 0.48 mm). Binary restenosis rate (final stenosis 2 50%) was 31.7% in 
stented pts in T vs 21.7% in P group (p--0.29) while was 15.6% in the balloon alone pts in T 
and 35.3% in P group (p=0.068). 
Conclusion. T seems not to influence clinical outcome of pts treated with elective balloon 
PTCA with/without stenting. Angiographic data suggest a possible favorable effect on rest- 
enosis only in pts treated with balloon PTCA alone. 
1125-5 Safety Profile of Glycoprotein lib/Ilia Inhibitors in 
Octogenerians 
H. Mehrdad Sadeohi, Kishore J. Harjai, Harish R. Chandra. Robert D. Safian, William W. 
O'Neill, Cindy L. Gnnes, William Beaumont Hospital, Royal Oak, Michigan. 
Background: Patients > 80 years-old constitute a growing population with CAD who have 
higher complication rates during percutaneous interventions (PCI). While glyooprotein 
lib/Ilia receptor inhibitors (GPI) are increasingly utilized to reduce the incidence of 
isshemic complications after PCI, there is limited data regarding the use of GPf in this 
group, especially with respect to the risk of intrecranial hemorrhage. We looked at the 
safety profile of GPI in a cohort of octo-& nanogenerians undergoing PCI. Methods: All 
consecutive pts 2 80 years-old undergoing PCI with or without a GPI at William Beau- 
mont Hospital dudng the period of January 1998 and June 2001 were evaluated for clini- 
cal outcomes and bleeding complications. Results: 1392 consecutive pts _> 80 years-old 
underwent PCI with a GPI (n=459) and without a GPI (n=933). Patients treated with a 
GP I  were more likely to be male (57% vs 48%) but less likely to have peripheral vascular 
disease (19% vs 25%). However, there were no baseline differences between the 2 
groups with respect to age (83), hypertension (71% vs 75%), diabetes (26% vs 27%), 
stroke, ulcer disease, hematocdt, or creatinine. Bleeding & transfusion rates are shown 
in the table below. Conclusions: Even though patients _> 80 years-old treated with Glyco- 
protein lib/Ilia receptor inhibitors have more minor bleeding, there is no increased risk of 
major bleeding requiring transfusions or intrecranial hemorrhage. GPI appear to be safe 
in octo-& nanogenerians undergoing PCI. 
RESULTS 
GPI n=459 NO GPI n=933 p value 
Hematoma 18% 13% 0.02 
GI/GU bleeds 10% 2.5% 0.004 
CNS bleeds 0% 0% NS 
Transfusion 10% 9% NS 
Transfused Unit per Bleed 2,3 2.2 NS 
Hospitalization length (days) 4.6+-4.6 4.5+-6.4 NS 
Death 3% 2.8% NS 
1125-6 Morta l i ty  Af ter  Percutaneous Coronary Intervention in 
Cardiogenic Shock: A Predictive Model Based on 1,869 
Consecutive Patients in the ACC-NCDR Registry 
Lloyd W. Klein. Ronald Krone, Peter Block, Ralph G. Brindle, Richard E. Shaw, Charles 
McKay, Kathleen Hewitt. William S. Weintraub, for the ACC-NCDR Registry, Rush- 
Presbyterian-St. Luke's Medical Center, Chicago, Illinois, 
Background: Although percutaneous coronary intervention (PCI) in the setting of cardio- 
genie shock (CSHOCK) has high in-hospital mortality, the identity and relative impor- 
tance of variables predictive of in-hospital death remain controversial. 
Methods: Accordingly, we queded the 100,000-plus patient ACC-NCDR registry col- 
lected in 1998-2000 and evaluated the procedures in 1,859 consecutive patients under- 
going PCI for CSHOCK. 
Results: The mean age was 66±13 years with males predominating (62%). 81% under- 
went PCI for urgent/emergent indication and 54% had ongoing rest angina. The mean 
LVEF in 1,149 patients with concurrent LV grams was 39±17%. PCI was performed on C- 
type lesions in 40% and B 2 lesions in 37%. Stents were placed in 71%, PCI at multiple 
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sites performed in 31%, and additional thrombolytic agents given in 23% of cases. PCI 
was angiographically successful in 86%, but the in-hospital mortality was 28%. The post- 
PCI length of stay was 7.0±9.7 days. Additionally, 1.7% had a CVA, 6.2% had renal fail- 
ure (RF), and 5.4% had vascular complications. Age was the single most predictive vari- 
able: mortality was 11.2% for ages up to 50; 20.0% for ages 51-60; 27.2% for ages 61- 
70; 34.8% for ages 71-80; 43.3% for ages above 80. Stenosis morphology (as A, B1, B 2 
or C) was not predictive. Logistic regression identified six muttivadate predictors of death: 
age (p<O.OOOl, odds ratio 1.45 (1.32, 1.60) for each 10 year increment); LVEF 
(p=O.0001, 0.76 (0.70, 0.62) for each 10% decrement); diabetes (p==O.O001, .65 (1.28, 
2.12)); RF(p=O.0005, 1.98 (1.35, 2.90)); pdor PCl (p=O.Ol, 0.69 (0.51, 0.93)); and urgent 
or emergent PC/(p<0.0001,0.32 (0.20, 0.53) and 2.54 (1.84, 3.51)). The model showed 
good discrimination with a ROC of 0.776, validated 0.736. Calibration was excellent, per- 
mitting development of a nomogram to estimate risk to over 60%. 
Conclusion: Thus, mortality after PCI for CSHOCK depends pdmarily on several histori- 
cal and clinical variables known to the physician at the time of decision for PCL Patients 
may be individually stratified as to risk of death. 
1125-7 Emergency CABG After Failed PCl in Contemporary 
Practice: A Report From the ACC-NCDR Regist ry  
Lloyd W. Klein, Michael A. Kutcher. Peter Block, Ronald Krone, William S. Weintraub, 
Richard E. Shaw, for the ACC-NCDR Registry, Rush-Presbyterian-St. Luke's Medical 
Center, Chicago,///inois. 
Background: The increased use of coronary stents and glycopretein IIb/Ina inhibitors over 
the past five years has resulted in a marked decrease in the need for emergency coronary 
artery bypass surgery (am CABG) after failed PCI. However, situations still occur that 
require the availability of surgical options. 
Methods: To characterize clinical and angiographic findings predisposing to em CABG in 
contemporary practice, the 100,263 consecutive PCI procedures performed from 1998- 
2000 at 145 institutions contained in the ACC-NCDR database were analyzed. 
ResultS: 371 (0.4%) of PCI procedures required am CABG. The average age was 63+12 
years, 64% were men, 7.0% had pdor CABG, and 27.8% prior PCI. Stents were placed in 
29.1% (vs. 71% in the total registry), lib/Ilia agents used in 41.2% and thromboiytics in 
11.0%. LV ejection fraction was 52:~12%. The indications for PCI included MI <6 hours 
duration in 16.4%, cardiogenic shock in 6.7%, and unstable angina in 62.8%. Interestingly, 
50.9% were considered elective PCI, while 24.0% were urgent and 25.1% emergent. 
Stanosis morphology assessed by AHNACC class showed 2.2% A, 28.9% B 1 , 32.9% B 2, 
and 36.1% C type lesions. When evaluated by SCAI class, 49.3% were non-C patent, 
23.5% were C patent, 14.6% nomC occluded, and 12.7% C occluded. Tamponade 
ocourredin 9.4%. In-hospital mortality was 11.1% and Q wave MI developed in 6.5%. Mul- 
tivadate predictors of in-hospital mortality after em CABG are shock (odds ratio 3.30, 95% 
CI 1.0-10.9, p=0.05), peripheral vaecu/ar disease (3.20, 1.2-8.5, p=0.02),/eft main disease 
(3.33, 1.1-10.2, p=0.03), and emergent indication (2.70, 1.02-7.12, p=0.05). 
Conclusion: The need for am CABG in contemporary PCI is very low, but when required it 
cardes sedous mortality and morbidity implications. A disturbing percentage of cases 
requidng em CABG consist of what are usually thought of as "low-dsk" elective procedures 
with non-complex stenosis morphologies and/or totally occluded vessels. Tamponade or 
the inability to deliver a stent may influence the decision process. Thus, there is still a role 
for surgical standby and em CABG options in contemporary practice. 
1125-8 A Double Blind Placebo-Controlled Randomized Trial of 
Fluvaststin After Successful Percutaneous Intervention 
in Patients With Coronary Heart Disease: The Lescol 
Intervention Prevention Study (LIPS) 
Patrick W. Serruvs, on behalf of the LIPS Investigators, Thoraxcenter, Erasmus 
University Hospita/, Rotterdam, The Netherlands. 
Background: Based on evidence from large clinical trials of subjects with and without 
coronary heart disease (CHD) or myocardial infarction (MI), statins are now well-estab- 
lished as the primary and secondary prevention of fatal and non-fatal coronary events; 
however, no study has prospectively evaluated the long-term effect of statins on clinical 
outcomes in patients who have undergone PCI. 
Methods: LIPS is a double-blind, randomized thai designed to compare the effect of flu- 
vastatin (40 mg bid) on major adverse cardiac event, ie MACE (cardiac death, non-fatal 
MI, repeat-CABG-or PCI)-free survival time in 1677 patients with CHD and successful 
TCT over a 3 year follow-up. Secondary endpoints are the incidence of MACE, non-car- 
diac deaths, hospitalization for other atherosclerotic diseases, changes in serum lipid 
concentrations, and anginal status. Inclusion cdtsria were: ages 18-80 years; first suc- 
cessful TCT within 6 months before randomization; total cholesterol of 135 - 270 mg/dL 
(3.5 - 7.0 mmol/L) with fasting triglycerides <400 mg/dL (<4.5 mmol/L) in the absence of 
any lipid-lowering therapy for at least 6 weeks. Baseline characteristics were as follows: 
Mean age (y) 60.5~_10 Anginal status (%) 
Male (%) 84.0 Unstable 49.7 
Smoking (%) 26.6 Stable 40.5 
Body Mass Index (kg/m 2) 26.6±3.3 Silent ischemia 9.8 
Blood pressure (mm Hg) 128.0/75.0 Previous MI 44.3 
Heart rate (bpm) 66.0+~11 Q-wave 26.8 
Diabetes mellitus (%) 12.0 Non Q-wave 17.6 
Totsl Number Of Lesions Treated 2222.0 
Summary: LIPS is the first study to investigate the effects of ststin therapy on MACE in 
patients who have undergone successful primary TCT for CHD. Final results will be pre- 
sented. 
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1125-9 Two-Year Outcomes Following Percutsneous 
Intervention: Beaumont Angiotsnsin Converting 
Enzyme Genotype and Endpoints Trial (The BAGET 
Trial) 
Kimbedv A. Skeldino. Laxmi Mehta, Demetris Demetriou, Domnita Cdsen, Judith A. 
Boura, Cindy L. Grines, William W. O'Neill, William Beaumont Hospital, Royal Oak, 
Michigan. 
Background: The angiotensin converting enzyme (ACE) genotype has been correlated 
with adverse cardiovascular events. This study was designed to determine if the ACE 
genotype was predictive of target vessel revascularization (TVR), myocardial infarction 
(MI), and mortality following percutaneous intervention. 
Methods: We prospectively analyzed the ACE genotype (D/D, D/I, I/I) in 756 patients 
undergoing percutaneous intervention to determine clinical restenosis and mortality at 
two year follow up. We analyzed baseline clinical parameters, angiographic details end 
outcomes in patients with D/D (255 patients) vs D/I (344 patients) vs I/I (154 patients). 
Results: Thus far in the D/D vs D/I vs I/I groups there is no difference in history of hyper- 
tension (76% vs 77% vs 71%, p=NS), hypedipidemia (76% vs 74% vs 83%, p=NS) or 
smoking (69% vs 74% vs 70%, p=NS). No difference in age (65+11, 65+11, 63+12, 
p=NS) or female gender (27% vs 24% vs 26%, p=NS) is seen. No difference in use of 
ACE inhibitors (46% vs 49% vs 42%, p=NS) or angiotensin receptor blockers (8% vs 
11% vs 14%, p=0.NS) is seen between the groups. History of diabetes mellitus (34% vs 
32% vs 33%, p=NS), coronary artery disease (85% vs 81% vs 84%, p=NS) and MI (53% 
vs 51% vs 54%, p=NS) are net different between groups. TVR is not affected by geno- 
type (23% vs 21% vs 15%, p=NS). The combined endpoint of TVR, MI and death did not 
differ by genotype as well (27% vs 26% vs 24%, p=NS). 
Conclusions: These findings sugggest that the ACE genotype does not correlate with 
TVR, MI or death at 2 years following percutaneous intervention. Therefore ACE geno- 
typing is not a useful test for risk stratification at the time of percutaneous intervention. 
1125-10 Gender Differences in Mortality After PTCA, According 
to  Age 
Emir Veledar. Jerome L. Abramson, Elizabeth M. Mahoney, William S. Weintraub, Viola 
Vaccarino, Emory University School of Medicine, Atlanta, Georgia. 
Background. Younger women hospitalized for myocardial infarction are a high-risk 
group compared to men, with higher short and long-term mortality. This gender difference 
is less pronounced at older ages. We sought to determine whether younger women are 
also at increased risk of in-hospital mortality after PTCA compared to men, and whether 
this gender difference becomes less pronounced with advancing age. 
Methods. We studied 150,919 patients included in the National Cardiovascular Network 
(NCN) database who received PTCA at 23 clinical centers between October, 1993, and 
June, 2000, and for whom outcome information was available. 
Results. In logistic regression models that adjusted for demographics, medical history, 
prior PTCA, prior CABG, height, weight, renal insufficiency, LVEF, number of diseased 
vessels and elective admission, women had a higher odds of death compared to men. 
This greater risk was most pronounced in the youngest age group. Among patients < 50 
years old, the odds of death was 2 times higher in women compared to men. However, 
this gender difference was less substantial in older age groups. 
Conclusion. Younger women undergoing PTCA are at a substantially higher risk of in- 
hospital mortality compared to younger men, even after adjustment for traditional risk 
factors. At older ages, women are at only slightly higher risk of mortality compared to 
men. The reasons for the higher post-PTCA mortality risk in young women compared to 
young men need investigation. 
In-Hospital Mortality After PTCA, According to Gender and Age 
Women Men 
Age N Mortality N Mortality Adjusted OR 95% CI 
Group Rate (%) Rate (%) (Women Vs. Men) 
<50 4776 0.8 17171 0.4 2.1 1.2-3.7 
50-59 8896 0.8 27210 0.6 1.4 0.9-2.0 
60-69 14374 1.2 29458 0.8 1.4 1.1-1.9 
70-79 16170 2.5 22451 1.8 1.2 0.9-1,5 
80+ 5453 4.2 4870 3.5 1.4 1.0-1,9 
